Long non-coding RNAs HERH-1 and HERH-4 facilitate cyclin A2 expression and accelerate cell cycle progression in advanced hepatocellular carcinoma

Tao Liu1,2*, Qiao Shi3, Lei Yang4, Shusen Wang1,2,5, Hongli Song5, Zhenglu Wang6, Xinnv Xu1, Hongsheng Liu1, Hong Zheng1,2,5 and Zhongyang Shen1,2,5*

Abstract

Background: The advanced hepatocellular carcinoma (HCC), such as the recurrent tumor after liver transplantation (LT), is an obstacle of HCC treatment. The aim of this study was to discover the underlying mechanism of HCC progression caused by non-coding RNAs (ncRNAs).

Methods: To this end, we investigated the selected patient cohort of matching primary and recurrent HCC after receiving LT. The recurrent tumors after LT were regarded as clinical models of the advanced HCC. Microarrays were used to profile lncRNA and mRNA expression in HCC recurrent and primary tissue samples. The mRNA profile characteristics were analyzed by bioinformatics. Two cell lines, HepG2 and QGY-7703, were used as HCC cell models. The protein-coding potential, length, and subcellular location of the interested IncRNAs were examined by bioinformatics, Northern blot, fluorescent in situ hybridization (FISH), and quantitative RT-PCR (qRT-PCR) assays. HCC cell proliferation was detected by CCK-8, doubling time and proliferation marker gene quantitation assays. DNA replication during the cell cycle was measured by Edu/PI staining and flow cytometry analyses. Promoter activity was measured using a luciferase reporter assay. Interactions between DNA, RNA, and protein were examined by immunoprecipitation and pull-down assays. The miRNA-target regulation was validated by a fluorescent reporter assay.

Results: Both lncRNA and mRNA profiles exhibited characteristic alterations in the recurrent tumor cells compared with the primary HCC. The mRNA profile in the HCC recurrent tissues, which served as model of advanced HCC, showed an aberrant cell cycle regulation. Two lncRNAs, the highly expressed lncRNA in recurrent HCC (HERH)-1 and HERH-4, were upregulated in the advanced HCC cells. HERH-1/4 enhanced proliferation and promoted DNA replication and G1-S transition during the cell cycle in HCC cells. HERH-1 interacted with the transcription factor CREB1. CREB1 enhanced cyclin A2 (CCNA2) transcription, depending on HERH-1-CREB1 interaction. HERH-4 acted as an miR-29b/c sponge to facilitate CCNA2 protein translation through a competing endogenous RNA (ceRNA) pathway.

© The Author(s). 2021 Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data.

* Correspondence: liutao@nankai.edu.cn; zhongyangshen@vip.sina.com
1National Health Commission’s Key Laboratory of Critical Care Medicine, Tianjin First Central Hospital, School of Medicine, Nankai University, No. 24 Fukang Road, Nankai District, Tianjin 300192, China
Full list of author information is available at the end of the article

Liu et al. BMC Cancer (2021) 21:957
https://doi.org/10.1186/s12885-021-08714-7
Conclusions: The oncogenic IncRNA HERH-1/4 promoted CCNA2 expression at the transcriptional and post-transcriptional levels and accelerated cell cycle progression in HCC cells. The HERH-1-CREB1-CCNA2 and HERH-4-miR-29b/c-CCNA2 axes served as molecular stimuli for HCC advance.

Keywords: Hepatocellular carcinoma, Cancer progression, Long non-coding RNA, Cell cycle

Background
Hepatocellular carcinoma (HCC) is now the second leading cause of cancer death worldwide [1]. Aggression and postoperative recurrence are significant characteristics of HCC [2], and treatment of the advanced HCC remains as a challenge [3]. Liver transplantation (LT) is a common curative approach for HCC treatment. However, about 8–16% of HCC patients undergoing LT developed tumor recurrence [4–6]. During HCC recurrence, the potentially residual tumor cells in the micrometastasis or in circulation can migrate to the graft liver or extrahepatic organs, locate, and finally form a recurrent tumor, indicating an intense progression of these cells. The overall survival time after HCC recurrence is only 12.97 months [4]. Therefore, the analysis of recurrent HCCs after LT can help to explore new mechanisms of advanced hepatocarcinogenesis in order to gain insights into tumor progression.

The factors that drive HCC cells to become more aggressive are the alteration of molecular characteristics, such as cancer genome and gene regulation [7, 8]. The evolution of molecular expression and phenotype of HCC cells can be regarded as tumor heterogeneity [7]. Non-coding RNAs (ncRNAs), which refer to the RNA transcripts that lack significant protein-coding potential, are found to mediate various cellular processes in cancers [9]. Long non-coding RNAs (lncRNAs) are ncRNA transcripts that are longer than 200 nucleotides (nt). By interacting with proteins, DNA and other RNA molecules, lncRNAs widely carry out their biological roles at epigenetic, transcriptional, and post-transcriptional levels [10–13]. Some lncRNAs have been identified to be related to HCC progression, such as tumor recurrence after LT [14–16]. MicroRNAs (miRNAs, miR) are another class of small ncRNAs that bind with other RNA transcripts, either mRNAs or other ncRNAs, to inhibit protein translation or lead to degradation of target RNAs [17]. High-throughput screening discovered several miRNAs that serve as biomarkers of tumor recurrence risk after LT [18, 19]. The levels of some miRNAs in circulation or in serum exosomes are also indicative of HCC recurrence risk [20, 21]. However, the reported ncRNAs were mostly regarded as biomarkers in HCC advance and recurrence, and the underlying molecular pathway has not been adequately elucidated.

In this study, we found that two lncRNAs, HERH-1 and HERH-4, were highly expressed in the advanced HCC cells. These two lncRNAs promoted HCC cell cycle progression by facilitating CCNA2 expression, which may sequentially accelerate HCC progression.

Methods
Clinical tissue samples
Twelve pairs of human HCC tissue samples, including HCC primary and recurrent tissues from patients undergoing liver transplantation (Table S1), were obtained from the Biological Sample Resource Sharing Center (BSRSC) of the Tianjin First Central Hospital with the patients’ informed consent. After surgical resection or biopsy, the tissue samples were flash-frozen in liquid nitrogen and then stored at −80°C until use. Two pairs of the tissues were applied in microarray analysis, and the other ten pairs were used in the following quantitative reverse transcription PCR (qRT-PCR) for validation of the dysregulated lncRNAs. This study was performed in accordance with the Declaration of Helsinki and was approved by the Ethics Committee of the Tianjin First Central Hospital.

HCC cell lines and transfection
An immortalized human benign hepatocyte cell line HL-7702, and four human HCC cell lines HepG2, QGY-7703, SMMC-7721 and Huh-7 were obtained from the Cell Bank of the Chinese Academy of Sciences (Shanghai, China) with confirmed identities of these cell lines. These cell lines were maintained in DMEM (Solarbio, Beijing, China; for HL-7702, HepG2 and Huh-7) or RPMI-1640 medium (Solarbio; for QGY-7703 and SMMC-7721) supplemented with 10% fetal bovine serum (FBS; Biowest, Nuaille, France) at 37°C in a humidified chamber supplemented with 5% CO₂. Transfection of plasmids or oligonucleotides was performed using Lipofectamine 2000 (ThermoFisher, Waltham, MA, USA).

RNA extraction
RNA was extracted from HCC tissues and cell lines using the mirVana™ miRNA Isolation Kit (ThermoFisher), according to the manufacturer’s instructions. Long (>200 nt) and short (<200 nt) RNAs were isolated and purified. The separation of cytoplasmic and nucleic RNAs was achieved using a Cytoplasmic and Nuclear RNA Purification Kit (Norgen, Thorold, ON, Canada).
Microarray analysis
Complementary DNA (cDNA) labeled with Cy3-dCTP (for primary HCC) or Cy5-dCTP (for recurrent HCC) was produced by Eberwine’s linear RNA amplification method and subsequent enzymatic reaction using a cRNA Amplification and Labeling Kit (CapitalBio, Beijing, China) [22]. The labeled cDNA was hybridized with CapitalBio Technology Human LncRNA Array V4 containing probes inspecting about 41,000 human lncRNAs and approximately 34,000 human mRNAs. Microarray data were analyzed using the GeneSpring software V13.0 (Agilent, Santa Clara, CA, USA). Genes with an absolute fold change value ≥2 and a Benjamin-Hochberg corrected P- value ≤0.05 were treated as differentially expressed genes. Hierarchical clustering analysis was performed using Cluster 3.0 software (Stanford University, CA, USA).

qRT-PCR
For quantification of lncRNAs and protein-coding genes, 5 μg of long RNA was reverse transcribed into cDNA using oligo dT (for mRNAs) or Random 6 (for lncRNAs) primers using a PrimeScript II 1st Strand cDNA Synthesis Kit (TaKaRa, Otsu, Shiga, Japan). The cDNA was then used for amplification of the target RNA. β-actin was used as an endogenous control. Quantification of miRNAs and endogenous control U6 snRNA was performed using the stem-loop RT-PCR method [23]. All the qRT-PCR tests were carried out in two independent experiments with each PCR reaction performed in duplicate. The sequence of all primers and oligonucleotides used in this study are provided in Table S2.

All the real-time quantitative PCRs were performed using TB Green Premix Ex Taq II (TaKaRa) on a LightCycler 96 Real-Time PCR System (Roche, Basel, Switzerland). Gene expression was analyzed using LightCycler 96 software (V1.1, Roche).

Northern blot assay
The lncRNA length was evaluated by Northern blot using a NorthernMax Kit (ThermoFisher). The exon fragments were amplified by PCR using human genomic DNA as a template. The fragments were then cloned into the pcDNA3.1(+) plasmid (Fig. S1). Suppression of endogenous lncRNAs was achieved by transfecting synthesized siRNA into HCC cells.

A double-strand RNA fragment was synthesized to serve as mimic of the miR-29b/c. A 2′-O-methyl modified single-strand RNA fragment that was inversely complementary to mature miR-29b/c (antisense oligonucleotide, ASO) was synthesized to serve as miR-29b/c inhibitor. These oligonucleotides were induced into HCC cells to artificially change miR-29b/c levels.

Overexpression of protein-coding genes was also achieved using the pcDNA3.1(+) vector. The full-length coding sequence was amplified by PCR using a human cDNA library as a template. The fragment was then cloned into the pcDNA3.1(+) plasmid.

Cell counting kit-8 (CCK-8) cell viability assay
HCC cells were planted into 24-well plate at 8 × 10^4 (HepG2) or 4 × 10^4 (QGY-7703) per well. The transfected HCC cells were fixed in 4% paraformaldehyde and incubated in 0.5% Triton X-100 for higher membrane permeability. After prehybridization, the cells were incubated with Ribo lncRNA FISH Probe Mix (Ribobio) at 37 °C overnight. After stringency washing and DAPI staining, fluorescence was observed under an IX71 fluorescence microscope (Olympus, Shinjuku, Japan).

Bioinformatics analyses
The protein-coding potential was assessed using the ORFinder (https://www.ncbi.nlm.nih.gov/orffinder/) and CPAT (http://labib.research.bcm.edu/cpat/index.php) databases. The concordance of HCC gene profiles from microarray data with defined gene sets was analyzed using the Gene Set Enrichment Analysis (GSEA) database (https://www.gsea-msigdb.org/gsea/index.jsp) [24]. Potential TFs or miRNAs binding with lncRNA were predicted using the RegRNA 2.0 database (http://regrna2.mbc.nctu.edu.tw/detection.html) [25]. The gene promoter region was predicted using PROMO (http://alggen.lsi.upc.es/cgi-bin/promo_v3/promominit.cgi?dirDB=TF_8.3) [26], and potential TFs binding with the gene promoter were predicted using PROMO and GeneCards (https://www.genecards.org/) [27]. The DNA-binding preferences of TFs were analyzed by JASPAR (http://jaspar.genereg.net/) [28]. Potential targets of miRNA were predicted using the TargetScanHuman database (http://www.targetscan.org/) [29].
(HepG2) or $5 \times 10^5$ (QGY-7703) per well with three duplicates for each group. All the CCK-8 tests were carried out in three independent experiments. HCC cell viability was detected using the CCK-8 reagent (Dojindo, Tokyo, Japan). The absorbance at 450 nm ($A_{450}$) was measured using an EnSpire Multimode Plate Reader (PerkinElmer, Waltham, MA, USA).

**Cell doubling time detection**

The HCC cells were planted and treated similarly as the CCK-8 assay. At 24 h and 48 h after planting, the number of cells in each well of the 96-well plate was accurately counted. The doubling time was calculated using the formula: doubling time = $\Delta t(lg2/(lgN_t-lgN_0))$, in which $\Delta t$ is the interval between the cell counting (24 h in this experiment), and $N_0$ and $N_t$ are the cell numbers at 24 h and 48 h after planting, respectively. All the cell doubling time tests were carried out in three independent experiments with each group in triplicate.

**5-Ethynyl-2'-deoxyuridine (EdU) cell proliferation assays**

As a kind of thymidine analog, EdU incorporates into genome DNA in the S phase during DNA synthesis. The quantity of the incorporated EdU reflects cell proliferation activity. EdU staining of HCC cells was performed using the Cell-Light EdU Apollo488 In Vitro Flow Cytometry Kit or Cell-Light EdU Apollo488 In Vitro Kit (Ribobio). For the flow cytometry analysis, HCC cells were planted into 6-well plate at $3 \times 10^5$ (HepG2) or $1.5 \times 10^5$ (QGY-7703) per well. The cells were transfected, stained and analyzed using an Accuri C6 Plus flow cytometer (BD, San Jose, CA, USA). For imaging, the HCC cells were treated and analyzed similarly as the CCK-8 assay. The cells in 96-well plate were stained and captured under an IX71 fluorescence microscope (Olympus). Fluorescence intensity was quantified using ImageJ software. The EdU cytometry and imaging tests were performed in two independent experiments with each group in duplicate.

**Propidium iodide (PI) staining cell cycle analysis**

HCC cells were planted into 6-well plate at $3 \times 10^5$ (HepG2) or $1.5 \times 10^5$ (QGY-7703) per well. Approximately $10^6$ transfected HCC cells were fixed in 70% ethanol for at least 2 h. After washing with PBS, cells were stained in 1 mL PI staining solution containing 10 $\mu$g/mL of PI, 100 $\mu$g/mL of RNase A, and 0.1% Triton X-100 dissolved in PBS, for 30 min in the dark. Cell cycle distribution was analyzed by flow cytometry using an Accuri C6 Plus flow cytometer (BD). The cell cycle tests were performed in two independent experiments with each group in duplicate.

**Gene promoter efficiency analysis**

The predicted CCNA2 promoter region was amplified by PCR and cloned into the pGL3/Enhancer vector (Promega, Madison, WI, USA). In addition, a CCNA2 promoter with deleted CREB1 binding sites was also amplified and cloned into the reporter vector. HCC cells were planted into 24-well plate at $8 \times 10^4$ (HepG2) or $4 \times 10^4$ (QGY-7703) per well. The reporter plasmids were transfected into HCC cells and the promoter efficiency was evaluated by measuring the luciferase activity using a Luciferase Assay System (Promega). Chemiluminescence was measured using an EnSpire Multimode Plate Reader (PerkinElmer). The gene promoter efficiency tests were performed in three independent experiments with each group in triplicate.

**Chromatin immunoprecipitation (ChIP) assay**

The interaction between TF and gene promoter was confirmed by ChIP assay using ab500 ChIP Kit (Abcam, Cambridge, UK) according to the manufacturer’s instructions. Approximately $1 \times 10^6$ HCC cells were collected for each ChIP assay. The TF conjugated DNA fragments were purified and the target DNA was identified using quantitative PCR.

**RNA pull-down assay**

The interaction between lncRNA and TF was detected by RNA pull-down assay using a Pierce Magnetic RNA-Protein Pull-Down Kit (ThermoFisher) according to the manufacturer’s instructions. Approximately $6 \times 10^6$ HCC cells were collected for each RNA pull-down assay. The potential RNA-binding proteins were eluted and purified for the further Western blot analysis.

**Western blot assay**

Protein samples were resolved on an SDS denaturing polyacrylamide gel and transferred onto a nitrocellulose membrane (Boster, Wuhan, China). The membrane was incubated with the primary antibody overnight at 4°C. The membrane was then washed and incubated with horseradish peroxidase (HRP)-conjugated secondary antibody. After chemiluminescence, the bands were captured using a ChemiDoc XRS+ imaging system (Bio-Rad). The band intensity was quantified using AlphaView SA software V3.4.0 (ProteinSimple, San Jose, CA, USA).

**RNA immunoprecipitation (RIP) assay**

RNA targets of RNA-binding proteins were identified using a Magna RIP RNA-Binding Protein Immunoprecipitation Kit (Millipore, Billerica, MA, USA), following the manufacturer’s instructions. Approximately $2 \times 10^7$ HCC cells were collected for each RIP assay. RNA in the RBP immunoprecipitation was purified and the target
Fig. 1 (See legend on next page.)
RNA was analyzed via RT-PCR and agarose gel electrophoresis.

**miRNA-target fluorescent reporter assay**
HCC cells were planted into 24-well plate at 8 × 10^4 (HepG2) or 4 × 10^5 (QGY-7703) per well. After 24 h, the cells were transfected with a GFP reporter vector along with associated plasmids or oligonucleotides. At 48 h after transfection, the cells were lysed with RIPA lysis buffer (Solarbio) and GFP intensity was measured using an EnSpire Multimode Plate Reader (PerkinElmer). The fluorescent reporter assays were performed in three individual experiments with each group in triplicate.

**Statistical analysis**
All numerical values were recorded as mean ± standard deviation (SD). The hypothesis test for significance between two groups utilized the Student’s t test. For three or more groups, one-way analysis of variance (ANOVA) was applied, followed by the Student-Newman-Keuls q test for comparing two of these groups. Statistical significance was set at P < 0.05. Data processing and figure drawing were performed using a GraphPad Prism 7 software (GraphPad Software, La Jolla, CA, USA).

**Results**
**HERH-1 and HERH-4 were expressed at a higher level in the advanced HCC**
The HCC recurrent tissues after LT were treated as typical clinical models of the advanced HCC. To assess the role of lncRNAs for advanced HCC, we investigated a patient sample set of 12 matching HCC primary and recurrent tissues by microarray and following qRT-PCR validation. The microarray analysis from two pairs of HCC tissues revealed that 716 IncRNAs and 2090 mRNAs were upregulated, and 997 IncRNAs and 958 mRNAs were downregulated in HCC recurrent tissues compared with the associated primary tumor tissues (Fig. S2; GEO accession: GSE102759). The cluster analysis indicated that the four HCC tissues could be grouped into two clusters as HCC recurrent and primary tissues (Fig. 1a). We selected the top five mostly dysregulated IncRNAs that have been noted in the Ensembl GRCh37 database (Table S3), and two of these IncRNAs showed good concordance with the microarray data by qRT-PCR in the other ten pairs of HCC tissues. We chose these two IncRNAs for further study, and named them as highly expressed IncRNAs in recurrent HCC (HERH)-1 and HERH-4 (Fig. 1b, c; Fig. S3; Table S4). Bioinformatics analysis indicated that HERH-1/4 lacked protein-coding potential (Table S5). HERH-1/4 was significantly induced in all the four human HCC cell lines compared to the immortalized, but benign hepatocyte cell line HL-7702, while HepG2 and QGY-7703 cells exhibited highest levels of HERH-1/4 (Fig. 1d). These two cell lines were applied in the following mechanistic studies.

Northern blot assays confirmed the existence of the two IncRNAs in HCC cells, and the length was in accordance with the prediction by the Ensembl GRCh37 database (Fig. 1e). More importantly, we found that HERH-1 was mainly located in the nucleus of HCC cells. HERH-4 appeared to be located in both the nucleus and the cytoplasm according to the FISH images. However, qRT-PCR assay confirmed that HERH-4 was mainly located in the cytoplasm of HCC cells (Fig. 1f, g). This indicated their possible functional patterns in the advanced HCC cells.

In order to determine the phenotypes that exhibited dominant alterations in the advanced HCC cells, we applied the GSEA database to analyze the mRNA profile (Table S6). Compared with the primary HCC, the mRNA expression pattern of the HCC recurrent tissues showed more similarity with that of the cells in which the RB gene was inhibited (Fig. 1h, Table S7). As a tumor suppressor, RB is a negative regulator of the cell cycle [30]. We presumed that the advanced HCC cells probably displayed an accelerated cell cycle progression.

**IncRNAs HERH-1/4 promoted HCC cell cycle progression**
We used pcDNA3 eukaryotic expression vectors (Fig. S1) and small interfering RNAs (siRNAs) to achieve gain-of-function and loss-of-function of the two IncRNAs, respectively, in HCC cell lines (Fig. S4). Both HERH-1 and HERH-4 enhanced the viability and shortened the doubling time of HepG2 and QGY-7703 cells (Fig. 2a, b). MKI67 is a marker for general cell cycle activity and is expressed through G1–M phase. PCNA is expressed in cells undergoing DNA
replication during S phase or DNA repair processes. The levels of these two proliferation marker genes also indicated positive regulation of these two IncRNAs on the proliferation of HCC cells (Fig. 2c). Genome DNA replication is a key process during cell proliferation. EdU cell proliferation assays suggested that HERH-1/4 levels were positively associated with the DNA replication rate (Fig. 2d, e). Furthermore, HERH-1/4 also affected the HCC cell cycle distribution. These two IncRNAs reduced HCC cells in the G1 phase, and increased those in the S phase, indicating a promoted G1-S transition. The number of cells in the G2/M phase was not affected by the IncRNAs (Fig. 2f). These data indicated that...
that induced HERH-1/4 expression is associated with enhanced cell cycle and S phase activity.

HERH-1 bound with CREB1 and facilitated CREB1-mediated CCNA2 transcription enhancement

Next, we tended to find out the functional protein-coding genes that were regulated by the lncRNAs HERH-1/4. It was presumed that the significant genes were probably involved in cell cycle process, and might be dysregulated in the advanced HCC cells. First, we searched the GSEA database and found that the gene set CELL_CYCLE_GO_0007049 records 315 genes annotated to the cell cycle (Table S8). Then, by combining our microarray data with this gene set, we screened out the potential TFs that can bind with HERH-1 and the CCNA2 promoter were predicted by bioinformatics. Among them, CCNA2 was the selected gene in the following study. To validate the predicted interaction, we combined this gene set with our microarray data, we screened out the top five significantly dysregulated cell cycle-associated genes in the advanced HCC, and part of these genes may be regulated by HERH-1/4.

Among them, CCNA2 was the selected gene in the following study. As predicted, CREB1 enhanced cell viability (Fig. 3a), shortened the cell doubling time (Fig. 3d), accelerated genome DNA replication (Fig. 4e, f), and promoted the transition of cells from the G1 phase to the S phase (Fig. 4g) in HCC cell lines. In addition, when endogenous HERH-1 was knocked down (Fig. 4a, b), CREB1 enhanced cell viability (Fig. 4c), shortened the cell doubling time (Fig. 4d), accelerated genome DNA replication (Fig. 4e, f), and promoted the transition of cells from the G1 phase to the S phase (Fig. 4g) in HCC cell lines. In addition, when endogenous HERH-1 was knocked down, the oncogenic effects of the CREB1 protein on HCC cells were no longer detectable (Fig. 4c–g). These results further demonstrated that HERH-1 facilitated CCNA2 expression by assisting CREB1 in CCNA2 transcription activity.
HERH-4 acted as a miR-29b/c sponge to stabilize CCNA2 mRNA and assisted its translation. Given that lncRNA HERH-4 is located in the cytoplasm, we explored its mechanism of HCC proliferation at the post-transcriptional level. According to the RegRNA 2.0 database, we found five miRNAs that possibly bound to HERH-4, and miR-29c-3p (miR-29c) had the highest score (Table S12). To search for the potential ceRNA of CCNA2, CREB1 promoted CCNA2 expression and enhanced HCC cell cycle progression depending on HERH-1. CREB1 was overexpressed in HCC cells with or without HERH-1 inhibition, and phenotypes of the HCC cells were detected to confirm the dependence of CREB1-assisted CCNA2 expression and function on HERH-1. a, b The endogenous CCNA2 level was measured by qRT-PCR (a, n = 2) and Western blot (b) assays. Full-length blots are presented in Fig. S8b. c, d The HCC cell viability and proliferation rate were detected by CCK-8 (c, n = 3) and doubling time (d, n = 3) assays. e, f DNA replication in HCC cells was detected by EdU staining and flow cytometry (e, n = 2) or fluorescence microscopy (f, n = 2). Scale bar, 20 μm. g The HCC cell cycle distribution was detected by PI staining and flow cytometry analysis (n = 2). *P < 0.05; **P < 0.01; n.s., not significant.
Fig. 5 (See legend on next page.)
HERH-4, we used the TargetScan database to predict miR-29-3p targets, and used the GSEA database to identify the cell cycle-associated genes. In addition, we focused on the upregulated protein-coding genes in the microarray because a high HERH-4 level reasonably led to an increase in its ceRNA [31]. As a result, three genes, including CCNA2, were present in all these three gene sets (Fig. 5a; Table S13). The miR-29b is an analog of miR-29c, and they share the same seed region. The levels of miR-29b/c were artificially altered by introducing mimics or ASOs into HCC cells (Fig. S7). miR-29b/c suppressed HERH-4 level by interacting with the predicted miRNA response element (MRE; Fig. 5b). Endogenous HERH-4 was negatively regulated by miR-29b/c (Fig. 5c). Similarly, CCNA2 expression was directly suppressed by miR-29b/c (Fig. 5d, e). These data confirmed that both HERH-4 and CCNA2 mRNA were direct targets of miR-29b/c.

In order to validate that HERH-4 positively regulated CCNA2 expression via absorbing miR-29b/c, we overexpressed the miR-29b/c response elements within HERH-4 in HCC cells. We found the GFP reporter intensity to be increased with CCNA2 wild-type MRE, while further induction of miR-29b/c reduced the GFP intensity to basal level. The positive regulation of HERH-4 MRE on CCNA2 was undetectable when the sequence of either HERH-4 MRE or CCNA2 MRE was mutated (Fig. 5f). Endogenous CCNA2 expression was also regulated by HERH-4 MRE and miR-29b/c following the same model (Fig. 5g).

An optimal ceRNA cross-talk occurs at a near-equimolar equilibrium of all ceRNAs and miRNAs within a network [32]. Absolute quantification indicated that the four molecules involved in the ceRNA network had comparable levels in HCC cells (Fig. 5h). The RIP experiment demonstrated that all the four molecules were recruited to AGO2 protein (Fig. 5i), a key factor in the RNA-induced silencing complex in which miRNAs exert their function. These data further supported the ceRNA network between HERH-4 and CCNA2.

**HERH-4 promoted HCC cell cycle progression by absorbing miR-29b/c**

In order to analyze the effects of the HERH-4-miR-29b/c-CCNA2 ceRNA network on HCC progression, we overexpressed the 22 nt length of the miR-29b/c binding sequence within HERH-4, and found a higher viability (Fig. 6a), a shorter doubling time (Fig. 6b), and a rapider genome DNA replication (Fig. 6c, d) in HCC cell lines. The mutated MRE sequence failed to promote HCC cell proliferation (Fig. 6a–d). Importantly, if we introduced miR-29b/c mimics following overexpression of the wild-type HERH-4 MRE, the proliferation activity of the HCC cells restored (Fig. 6a–d). The wild-type rather than the mutated HERH-4 MRE reduced HCC cells in the G1 phase and increased those in the S phase, and miR-29b/c restored these effects (Fig. 6e). These data support the hypothesis that HERH-4 acts as a ceRNA to facilitate CCNA2 expression and promote HCC proliferation and cell cycle progression.

**Discussion**

The high aggression rate has been a significant obstacle for HCC treatment [4–6]. The recurrent HCC after LT is characterized as significantly enhanced progression, making it a typical model of the advanced HCC cells. Recurrence of HCC is indicative for HCC advancing and metastasis, which indicates worse prognosis of the patients. Therefore, the study intended to illustrate the underlying molecular mechanism in HCC recurring.

Interestingly, more than 60% of the human genome is transcribed, and the protein-coding genes account for only less than 2% of the genome [33, 34]. The non-protein-coding transcripts are extensively involved in many cellular pathways and processes, including onco-genic signaling [34]. In this study, we obtained the
HERH-4 promoted HCC cell cycle progression by absorbing miR-29b/c. The HERH-4 MRE sequence was overexpressed, with or without transfection of miR-29b/c mimics in HCC cells in order to validate the ceRNA regulation of HERH-4 on CCNA2 and the following effects of cell cycle associated phenotypes in HCC cells. 

a, b The HCC cell viability and proliferation rate were detected by CCK-8 (a, n = 3) and doubling time (b, n = 3) assays.

c, d DNA replication in HCC cells was detected by EdU staining and flow cytometry (c, n = 2) or fluorescence microscopy (d, n = 2). Scale bar, 20 μm.

e The HCC cell cycle distribution was detected by PI staining and flow cytometry analysis (n = 2). MRE, miRNA response element; NC, negative control; wt, wild-type; mut, mutant; *P < 0.05; **P < 0.01; n.s., not significant.
following messages through microarray data. First, both mRNA and lncRNA profiles in the recurrent tumor cells exhibited characteristic changes compared with those in the HCC primary tissues. Second, we identified that a significant biological feature of the recurrent tumor cells was acceleration of the cell cycle progression. The retinoblastoma (RB) family plays a pivotal role in the negative control of the cell cycle and in tumor progression [30]. The advanced HCC cells exhibited a similar mRNA profile as the cells in which the RB gene family is down-regulated, indicating a promoted cell cycle in these cells. Third, two of the obviously changed lncRNAs, named HERH-1 and HERH-4, were selected for mechanistic studies. lncRNAs can interact with RNA-binding proteins (RBPs) and regulate their function [35]. These lncRNAs are required for the correct localization of the TFs to genome DNA [36]. In HCC cells, transcription of the cell cycle regulator CCNA2 was accelerated by CREB1, and this regulation process was HERH-1-dependent. This hypothesis was verified by the following experiments. First, CCNA2 transcription was accelerated by
CREB1 protein, and this regulation depended on the three CREB1 binding motifs within the CCNA2 promoter. Second, HERH-1 directly interacted with CREB1 in a sequence-specific manner. Third, ectopic expression of CREB1 improved CCNA2 levels, promoted proliferation, and accelerated the cell cycle of HCC cells. Importantly, HERH-1 was essential in the CREB1-CCNA2 axis-mediated cell cycle acceleration. These data demonstrated that HERH-1 positively regulates CCNA2 expression and the HCC cell cycle at the transcriptional level.

IncRNA also acts as a negative regulator of miRNA [12, 13]. RNA transcripts can sequester a limited pool of special miRNAs and prevent other RNA molecules from being inhibited by these miRNAs, known as competing endogenous RNA (ceRNA) [31, 37, 38]. In HCC cells, the IncRNA HERH-4 acts as a natural miRNA decoy to promote CCNA2 expression at the post-transcriptional level. First, both HERH-4 and CCNA2 mRNA possess functional miR-29b/c binding sites. The miRNAs and their targets were all recruited to AGO2 protein, a key factor of RNA-induced silencing complex (RISC), in which the miRNA-targeted RNA molecules are degraded [39, 40]. Second, the MRE fragment within the HERH-4 sequence promoted CCNA2 gene expression, which was further restored by miR-29b/c mimics. Third, miR-29b/c and their two targets had comparable levels in HCC cells, which ensured an appropriate molecular environment for ceRNA cross-talk [32].

Cyclin is a classical protein family that controls cell cycle progression by activating cyclin-dependent kinase (CDK) enzymes or other cell cycle-associated factors. As a widely expressed cyclin A subtype, cyclin A2 (CCNA2) binds and activates CDK2 to control the G1/S transition [41]. Our research demonstrated two novel CCNA2 upstream regulation pathways involved in HCC progression. Another key regulator of G1/S transition cyclin E2 (CCNE2) was also upregulated in the advanced HCC (Table S9). The possible regulation of CCNE2 by HERH-1/4 are of importance to be explored in the future.

Conclusions
In summary, this study revealed two IncRNA-mediated cell cycle regulation pathways in the advanced HCC cells. During HCC evolution, the tumor cells exhibit accelerated cell cycle progression. The IncRNAs HERH-1/4 promoted HCC cell proliferation and the G1-S transition of the cell cycle. HERH-1 binds with CREB1 and assisted CCNA2 transcription. HERH-4 acted as an miR-29b/c decoy to alleviate the suppression of CCNA2 protein translation at the post-transcriptional level. The HERH-1/4-CCNA2 axis plays a crucial role during HCC progression (Fig. 7).

Abbreviations
AFP: Alpha-fetoprotein; ASO: Antisense oligonucleotide; CCK-8: Cell counting kit-8; CCNA2: Cyclin A2; ceRNA: Competing endogenous RNA; ChIP: Chromatin immunoprecipitation; CREB1: cAMP response element binding protein 1; CTC: Circulating tumor cell; EdU: 5-ethynyl-2′-deoxyuridine; FISH: Fluorescent in situ hybridization; GEO: Gene Expression Omnibus; GFP: Green fluorescent protein; GSEA: Gene Set Enrichment Analysis; HCC: Hepatocellular carcinoma; HERH: Highly expressed IncRNA in recurrent HCC; IncRNA: Long non-coding RNA; LT: Liver transplantation; miR/miRNA: MicroRNA; MRE: miRNA response element; ncRNA: Non-coding RNA; qRT-PCR: Quantitative reverse transcription – polymerase chain reaction; RB: Retinoblastoma; RIP: RNA immunoprecipitation; siR/siRNA: Small interfering RNA; TF: Transcription factor

Supplementary Information
The online version contains supplementary material available at https://doi.org/10.1186/s12885-021-08714-7.

Additional file 1.
Additional file 2.

Acknowledgements
Not applicable.

Authors’ contributions
TL, HZ and ZS conceived and designed the study. ZW collected the clinical tissue samples. TL, QS, LY and HL performed the cell biology and molecular biology experiments. SW, HS and ZW analyzed the data. TL organized figures and wrote the manuscript. All authors read and approved the final manuscript.

Funding
This work was supported by the National Natural Science Foundation of China (81402322), the Foundation for Key Laboratories of Chinese Academy of Medical Sciences (2018PT32021), and the Science Foundation of Tianjin First Central Hospital (2020CM01). The funding bodies were supportive to this work in terms of materials and reagents, data collection and analysis, and technical supports.

Availability of data and materials
The RNA microarray data generated and analyzed during the current study are available in the Gene Expression Omnibus (GEO) repository (https://www.ncbi.nlm.nih.gov/geo; accession: GSE102759). All data that support the findings of this study are available from the corresponding authors upon reasonable request.

Declarations
Ethics approval and consent to participate
The human HCC tissue samples were obtained with the patients’ informed consent and applied in accordance with the Declaration of Helsinki. The ethics approval statements for human subjects were approved by the Ethics Committee of Tianjin First Central Hospital.

Consent for publication
Not applicable.

Competing interests
The authors declare that they have no competing interests.

Author details
1National Health Commission’s Key Laboratory of Critical Care Medicine, Tianjin First Central Hospital, School of Medicine, Nankai University, No. 24 Fushing Road, Nankai District, Tianjin 300192, China. 2Key Laboratory of Transplant Medicine, Chinese Academy of Medical Sciences, Tianjin First Central Hospital, School of Medicine, Nankai University, Tianjin 300192, China. 3Graduate School, Tianjin University of Traditional Chinese Medicine, Tianjin 301617, China. 4Department of Clinical Laboratory, Tianjin First Central Hospital, School of Medicine, Nankai University, Tianjin 300192, China. 5Organ...
Transplant Center, Tianjin First Central Hospital, School of Medicine, Nankai University, Tianjin 300192, China. *Biological Sample Resource Sharing Center (BSRSC), Tianjin First Central Hospital, School of Medicine, Nankai University, Tianjin 300192, China.

Received: 11 January 2021 Accepted: 18 August 2021

Published online: 26 August 2021

References

1. Wallace MC, Preen D, Jeffrey GP, Adams LA. The evolving epidemiology of hepatocellular carcinoma: a global perspective. Expert Rev Gastroenterol Hepatol. 2015;9(6):765–79. https://doi.org/10.1586/17474124.2015.1039636.

2. Critelli RM, De Maria N, Villa E. Biology of hepatocellular carcinoma. Dig Dis. 2015;33(5):635–41. https://doi.org/10.1159/000438472.

3. Colangarade S, Inghelis AL, Abuhas S, Taliani GG, Nardi C, Mama F. Challenges of advanced hepatocellular carcinoma. World J Gastroenterol. 2016;22(34):7645–50. https://doi.org/10.3748/wjg.v22.i34.7645.

4. de Angelis N, Landi F, Caneva D, Mancini M. Mechanisms of recurrent hepatocellular carcinoma after liver transplantation: a systematic review. World J Gastroenterol. 2015;21(39):11185–98. https://doi.org/10.3748/wjg.v21.i39.11185.

5. Chagas AL, Felga GEG, Diniz MA, Silva FR, Mattos AA, Silva R, et al. Hepatocellular carcinoma recurrence after liver transplantation in a Brazilian multicenter study: clinical profile and prognostic factors of survival. Eur J Gastroenterol Hepatol. 2019;31(9):1148–56. https://doi.org/10.1097/MEG.0000000000001448.

6. Foerster F, Hoppe-Lotichius M, Vollmar J, Marquardt JU, Weinmann A, Worns M, et al. Hepatocellular carcinoma recurrence rates and risk factors after liver transplantation at a European transplantation Centre. United European Gastroenterol J. 2016;29(3):369–74. https://doi.org/10.1177/1753228716672295.

7. Daggo-Lack J, Shav AT. Tumour heterogeneity and resistance to cancer therapies. Nat Rev Clin Oncol. 2018;15(2):81–94. https://doi.org/10.1038/s41571-017-0052-x.

8. Marusyk A, Almendro V, Polyak K. Intra-tumour heterogeneity: a looking glass for cancer? Nat Rev Cancer. 2012;12(5):323–34. https://doi.org/10.1038/nrc3361.

9. Anastasiadou E, Jacobs L, Slack FJ. Non-coding RNA networks in cancer. Nat Rev Cancer. 2018;18(1):5–15. https://doi.org/10.1038/s41579-017-0006-4.

10. Kent JT, Colognori D, Lee JT. Long non-coding RNAs: past, present, and future. Genetics. 2013;193(3):651–69. https://doi.org/10.1534/genetics.112.146704.

11. Janardana A, Krause HM. The new RNA world: growing evidence for long non-coding RNA functionality. Trends Genet. 2017;33(10):665–76. https://doi.org/10.1016/j.tig.2017.08.002.

12. Jandura A, Krause HM. The new RNA world: growing evidence for long non-coding RNA functionality. Trends Genet. 2017;33(10):665–76. https://doi.org/10.1016/j.tig.2017.08.002.

13. Dykes IM, Emanuelli C. Transcriptional and post-transcriptional gene regulation by long non-coding RNA. Genomics Proteomics Bioinformatics. 2015;13(3):177–86. https://doi.org/10.1007/j17999-015-0200-0.

14. Fang Y, Fullwood MJ. Roles, functions, and mechanisms of long non-coding RNAs in Cancer. Genomics Proteomics Bioinformatics. 2016;14(1):42–54. https://doi.org/10.1007/j17999-015-0200-0.

15. Yang Z, Zhou L, Wu LM, Lai MC, Xie HY, Zhang F, et al. Overexpression of long non-coding RNA HOTAIR predicts tumor recurrence in hepatocellular carcinoma patients following liver transplantation. Ann Surg Oncol. 2011;18(5):1243–50. https://doi.org/10.1245/s10434-011-1581-y.

16. Lai MC, Yang Z, Zhou L, Zhu QQ, Xie HY, Zhang F, et al. Long non-coding RNA MALAT-1 overexpression predicts tumor recurrence of hepatocellular carcinoma after liver transplantation. Med Oncol. 2012;29(3):1810–6. https://doi.org/10.1007/s12032-011-0004-y.

17. Wu L, Yang Z, Zhang J, Xie H, Zhou L, Zheng S. Long non-coding RNA HOTTIP expression predicts tumor recurrence in hepatocellular carcinoma patients following liver transplantation. Hepatobiliary Surg Nutr. 2018;7(6):429–39. https://doi.org/10.21037/hbsn.2018.1007.

18. Mohr AM, Ewell ML. Overview of microRNA biology. Semin Liver Dis. 2015;35(1):13–11. https://doi.org/10.1055/s-0035-1397344.

19. Xie QY, Almudevar A, Whitney-Miller CL, Barry CT, McCaill MN. A microRNA biomarker of hepatocellular carcinoma recurrence following liver transplantation accounting for within-patient heterogeneity. BMC Med Genet. 2016;17(1):118. https://doi.org/10.1186/s12881-016-0179-4.

20. Lisse J, Peveling-Oberjahr J, Deering C, Schnitzbauer AA, Herrmann E, Zangos S, et al. A possible role of microRNAs as predictive markers for the recurrence of hepatocellular carcinoma after liver transplantation. Transplant Int. 2016;29(5):369–80. https://doi.org/10.1111/tti.12733.

Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.